{"product_id":"sttk-vrio-analysis","title":"Shattuck Labs, Inc. (STTK): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Shattuck Labs, Inc. (STTK) truly positioned for sustainable success? Our rigorous VRIO analysis cuts straight to the core, examining whether its resources are Valuable, Rare, Inimitable, and Organized to capture a lasting competitive edge. Discover the definitive verdict on Shattuck Labs, Inc. (STTK)'s strategic strengths and weaknesses immediately below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eShattuck Labs, Inc. (STTK) - VRIO Analysis: First Core Capabilities \/ Resources: SL-325 Lead Drug Candidate (DR3 Antagonist)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at Shattuck Labs, Inc.'s main bet, SL-325, and trying to figure out if it’s a real game-changer or just another promising molecule. The core idea here is that SL-325, a Death Receptor 3 (DR3) blocking antibody, aims to completely shut down the DR3\/TL1A pathway, which is a big deal in Inflammatory Bowel Disease (IBD) and other autoimmune messes. Preclinical work suggests it has superior activity compared to just blocking the ligand, TL1A, which is a more common target right now. This is the foundation of their near-term value proposition.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Potential First-in-Class Blockade\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value is tied directly to clinical success, but the mechanism is compelling. If SL-325 delivers a complete and durable blockade of the DR3\/TL1A axis, it offers a potentially first-in-class treatment profile for IBD. Remember, the IND clearance happened in August 2025, and the first participants were dosed in the Phase 1 trial in the third quarter of 2025. That’s real progress moving from the bench to human trials.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Targeting the Receptor, Not Just the Ligand\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis is where Shattuck Labs has a leg up, at least for now. SL-325 became the \u003cstrong\u003efirst\u003c\/strong\u003e DR3 blocking antibody to enter clinical development in the third quarter of 2025. Most competitors are focused on TL1A antibodies. This direct targeting of the receptor (DR3) is less common, making the asset rare in the current clinical landscape. The path to Phase 2 trials in IBD is now funded, which is a critical step to validate this rarity.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInimitability: Patents and Development History\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImitability is low because the specific molecule is protected. Shattuck Labs has patents, like US12319742B1 granted in January 2024, covering antibodies that bind TNFRSF25 (DR3) with reduced agonistic activity. It’s not just the patent, though; it’s the entire development history - the specific humanization, the Fc-silencing, and the favorable non-human primate safety profile - that creates a barrier. You can’t just copy the data trail.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Focused Capital Allocation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is clearly structured around this asset. They closed a private placement of up to $103 million in August 2025 to specifically support SL-325 advancement. As of September 30, 2025, their cash and short-term investments stood at $86.1 million. Assuming full warrant exercise, this funding is expected to keep the lights on into 2029, covering the advancement through Phase 2 trials. That’s a clear organizational commitment and resource alignment.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on that financial focus: Q3 2025 R\u0026amp;D was $7.6 million, and the net loss was $10.1 million. They have the capital structure in place to execute the plan without immediate dilution pressure.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Awaiting Data Validation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRight now, the advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e. It’s a potential competitive advantage based on mechanism and early-stage lead status. However, this advantage hinges entirely on the upcoming Phase 1 data readout, which analysts expect in the second quarter of 2026. If that data confirms safety and suggests efficacy, the advantage shifts from temporary to sustained, assuming competitors are still behind. If it fails, the advantage vanishes.\u003c\/p\u003e\n\n\u003cp\u003eHere is a summary of the VRIO assessment for SL-325:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eKey Supporting Data \/ Metric (2025 FY)\u003c\/th\u003e\n    \u003cth\u003eScore Implication\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh Potential\u003c\/td\u003e\n    \u003ctd\u003eFirst DR3 blocking antibody in clinical development (Q3 2025 Dosing)\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Parity\/Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eDirect DR3 antagonism is less common than TL1A ligand targeting.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eInimitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eLow to Medium\u003c\/td\u003e\n    \u003ctd\u003eProtected by patents (e.g., US12319742B1) and proprietary development history.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eCash runway extends into \u003cstrong\u003e2029\u003c\/strong\u003e following $103 million private placement in August 2025.\u003c\/td\u003e\n    \u003ctd\u003eRealized Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eAdvantage sustained only until Phase 1 data delivery (expected Q2 2026).\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe immediate action for you is to track the Phase 1 enrollment completion, expected in the second quarter of 2026. That’s the inflection point. If onboarding takes longer than expected, the timeline for validating this asset slips, which definitely raises the risk profile.\u003c\/p\u003e\n\u003cp\u003eFinance: draft sensitivity analysis on cash burn rate if Phase 2 initiation is delayed past Q1 2027 by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eShattuck Labs, Inc. (STTK) - VRIO Analysis: Second Core Capabilities \/ Resources: Proprietary DR3\/TL1A Pathway Targeting Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows the company to pursue a clinically validated target with a potentially superior mechanism of action compared to competitors.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSL-325 is a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3\/TL1A pathway.\u003c\/li\u003e\n\u003cli\u003ePreclinical studies demonstrate SL-325 has high affinity binding and superior activity over TL1A antibodies.\u003c\/li\u003e\n\u003cli\u003eThe company expects current cash and investments of $86.1 million as of September 30, 2025, with proceeds from a private placement of up to $103 million (assuming full warrant exercise) to fund operations into 2029.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses were $7.6 million for the quarter ended September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; other firms target the pathway, but Shattuck Labs’ specific focus on the receptor (DR3) is distinct.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTargeting Approach\u003c\/td\u003e\n\u003ctd\u003eLead Programs Cited\u003c\/td\u003e\n\u003ctd\u003eClinical Stage (as of latest data)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTL1A Ligand Blocking (Competitors)\u003c\/td\u003e\n\u003ctd\u003eMerck \u0026amp; Co. Inc.'s tulisokibart, Roche Holdings AG's afimkibart\u003c\/td\u003e\n\u003ctd\u003eLate-stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDR3 Receptor Blocking (Shattuck)\u003c\/td\u003e\n\u003ctd\u003eSL-325\u003c\/td\u003e\n\u003ctd\u003ePhase 1 (First participants dosed in Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eConcerns around immunogenicity and anti-drug antibodies remain common constraints across the TL1A blocking class.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the underlying biological knowledge is shared, but the specific application and optimization are proprietary.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eShattuck’s expertise in protein engineering allowed it to effectively antagonize DR3, where others have struggled with receptor-level targeting.\u003c\/li\u003e\n\u003cli\u003eSL-325 is a fully Fc-silenced humanized immunoglobulin G monoclonal antibody.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this expertise informs the entire R\u0026amp;D strategy, including the bispecific pipeline development.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eShattuck continues to develop multiple preclinical DR3-based bispecific antibodies designed to inhibit both the DR3\/TL1A axis and another biologically relevant target for Inflammatory Bowel Disease (IBD).\u003c\/li\u003e\n\u003cli\u003eThe company plans to nominate a lead bispecific candidate from its preclinical pipeline in 2025.\u003c\/li\u003e\n\u003cli\u003ePhase 1 enrollment of the Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) portions of the SL-325 trial is expected to be completed in the second quarter of 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; deep, specialized knowledge in a niche area of immunology is hard to replicate quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBlocking the constitutively expressed DR3 receptor is expected to deliver more durable inflammatory control than ligand-level inhibition.\u003c\/li\u003e\n\u003cli\u003eThe company's net loss for Q3 2025 was $10.1 million ($0.14 per share).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eShattuck Labs, Inc. (STTK) - VRIO Analysis: Third Core Capabilities \/ Resources: Extended Financial Runway to 2029\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides stability to execute critical, long-duration clinical milestones without immediate dilution pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many clinical-stage biotechs have shorter runways; this is a significant buffer.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a result of a specific financing event, not an inherent operational trait.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management successfully closed an oversubscribed private placement of up to \u003cstrong\u003e$103 million\u003c\/strong\u003e in August 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the runway is finite, lasting into \u003cstrong\u003e2029\u003c\/strong\u003e based on current plans and assuming warrant exercise.\u003c\/p\u003e\n\u003cp\u003eThe financial underpinning for this extended runway stems from the August 2025 financing event, detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancing Component\u003c\/th\u003e\n\u003cth\u003eAmount \/ Detail\u003c\/th\u003e\n\u003cth\u003eDate \/ Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Gross Proceeds (Up To)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$103 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAugust 2025 Closing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead Investor\u003c\/td\u003e\n\u003ctd\u003eOrbiMed\u003c\/td\u003e\n\u003ctd\u003eAugust 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Runway (Pro Forma)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2029\u003c\/strong\u003e (Assuming full warrant exercise)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Use of Proceeds\u003c\/td\u003e\n\u003ctd\u003eAdvance SL-325 through multiple Phase 2 clinical trials\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe financial position as of the end of the third quarter of 2025 provides context for the runway projection:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents and short-term investments as of September 30, 2025: \u003cstrong\u003e$86.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInitial anticipated gross proceeds from the private placement: Approximately \u003cstrong\u003e$46 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAdditional potential gross proceeds from full exercise of accompanying common stock warrants: Up to approximately \u003cstrong\u003e$57 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCommon stock warrant exercise price: \u003cstrong\u003e$1.0846\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePre-funded warrant exercise price: \u003cstrong\u003e$0.0001\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eShattuck Labs, Inc. (STTK) - VRIO Analysis: Fourth Core Capabilities \/ Resources: Preclinical Bispecific Antibody Pipeline\n\u003c\/h2\u003e\n\n\u003cp\u003eThe preclinical bispecific antibody pipeline represents an extension of Shattuck Labs' core Death Receptor 3 (DR3) expertise, aiming to combine DR3\/TL1A axis inhibition with another biologically relevant target for Inflammatory Bowel Disease (IBD) treatment.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eCreates follow-on value beyond SL-325 by leveraging the core DR3 expertise for combination therapies.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate; many companies have platform technologies, but this is a focused extension of their core mechanism.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate; competitors can pursue bispecifics, but Shattuck Labs has a head start in this specific area.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eDevelopment is ongoing, with a lead bispecific candidate nomination planned for the \u003cstrong\u003efirst half of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary; it offers future optionality but requires further investment to mature into a true advantage.\u003c\/p\u003e\n\n\u003cp\u003eThe current status and financial backing supporting this pipeline development are summarized below:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead Bispecific Candidate Nomination Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFirst half of 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnticipated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 Enrollment Completion (SL-325)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSecond quarter of 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$86.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate Placement Financing Secured\u003c\/td\u003e\n\u003ctd\u003eUp to approximately \u003cstrong\u003e$103 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAugust 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePro Forma Cash Runway (Post-Financing)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2029\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAssuming full warrant exercise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey organizational milestones and financial context include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSL-325, the lead DR3 blocking antibody, entered clinical development in the third quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eThe company is developing multiple preclinical DR3-based bispecific antibodies.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D Expenses for Q3 2025 were \u003cstrong\u003e$7.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss for Q3 2025 was \u003cstrong\u003e$10.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eShattuck Labs, Inc. (STTK) - VRIO Analysis: Fifth Core Capabilities \/ Resources: Phase 1 Clinical Trial Execution Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates the ability to transition a drug from preclinical to human testing, a major de-risking event.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many small biotechs struggle with IND clearance and initial trial setup.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a one-time achievement based on regulatory submissions and operational readiness.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company achieved IND clearance in \u003cstrong\u003eAugust 2025\u003c\/strong\u003e and dosed first participants in the SAD portion of the Phase 1 trial in the \u003cstrong\u003ethird quarter of 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage is realized upon successful completion of the trial, not just initiation.\u003c\/p\u003e\n\u003cp\u003eThe execution capability is financially supported by recent capital raising activities:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate Placement Proceeds (Up to)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$103 million\u003c\/strong\u003e (Closed August 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Investments (As of September 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$86.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Investments (As of June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Funding Runway (Assuming full warrant exercise)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2029\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational metrics related to the Phase 1 trial execution and recent financial reporting include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIND clearance for SL-325: \u003cstrong\u003eAugust 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFirst participant dosed in SAD portion of Phase 1 trial: \u003cstrong\u003eThird quarter of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected completion of SAD and MAD enrollment portions of Phase 1 trial: \u003cstrong\u003eSecond quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected disclosure of initial Phase 1 results (Safety, PK, etc.): By \u003cstrong\u003esecond quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThird Quarter 2025 Financials:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss: \u003cstrong\u003e$10.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss Per Share (Basic and Diluted): \u003cstrong\u003e$0.14\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch \u0026amp; Development (R\u0026amp;D) Expenses: \u003cstrong\u003e$7.60 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGeneral \u0026amp; Administrative (G\u0026amp;A) Expenses: \u003cstrong\u003e$4.10 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eShattuck Labs, Inc. (STTK) - VRIO Analysis: Sixth Core Capabilities \/ Resources: Protein Engineering \u0026amp; TNF Superfamily Receptor Development Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The foundational scientific skill set that underpins the entire drug discovery engine.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many firms have protein engineering, but this is specialized in the TNF receptor class.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; deep, specialized talent pools are difficult, but not impossible, for large pharma to hire away.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this expertise is embedded in the company’s identity and informs the development of both SL-325 and the bispecifics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; core scientific competency is a long-term asset if maintained through hiring and culture.\u003c\/p\u003e\n\u003cp\u003eThe application of this expertise is evidenced by the progression of the lead candidate and the associated financial commitment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead Candidate Target\u003c\/td\u003e\n\u003ctd\u003eDeath Receptor 3 (DR3) Antagonist (SL-325)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Superiority Claim\u003c\/td\u003e\n\u003ctd\u003eSuperior efficacy over TL1A antibodies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND Filing Expectation\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 Trial Initiation\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 Enrollment Completion Expectation\u003c\/td\u003e\n\u003ctd\u003eQ2 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Investments (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$86.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway (assuming full warrant exercise)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2029\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe specialization within the TNF superfamily receptor space is demonstrated through platform utilization:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eARC® platform utilized for bispecific fusion proteins, such as SL-9258 (TIGIT-Fc-LIGHT).\u003c\/li\u003e\n\u003cli\u003eSL-325 is a fully Fc-silenced humanized immunoglobulin G monoclonal antibody.\u003c\/li\u003e\n\u003cli\u003eThe company's scientific program leaders have been with the company since \u003cstrong\u003e2017\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eA strategic realignment involved an approximate \u003cstrong\u003e40% reduction in workforce\u003c\/strong\u003e to focus resources.\u003c\/li\u003e\n\u003cli\u003eSL-325 is designed to achieve a complete and durable blockade of the clinically validated DR3\/TL1A pathway.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eShattuck Labs, Inc. (STTK) - VRIO Analysis: Seventh Core Capabilities \/ Resources: Recent Strategic Board Refreshment\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Adds high-level industry experience and strong financial backing representation to governance.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eRepresentation from OrbiMed Advisors LLC, an investment firm where Mona Ashiya, Ph.D. has served in various roles since \u003cstrong\u003e2010\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIndustry experience includes Daniel Baker, M.D.'s tenure as Vice President, Immunology R\u0026amp;D at Johnson \u0026amp; Johnson (Janssen\/Centocor) from \u003cstrong\u003e2000 to 2019\u003c\/strong\u003e, overseeing clinical development contributing to more than \u003cstrong\u003e15 regulatory approvals\u003c\/strong\u003e in the US, Europe and Japan.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; board changes are common, but these specific appointments are unique to STTK.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific individuals, Daniel Baker, M.D., and Mona Ashiya, Ph.D. (OrbiMed), cannot be imitated.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the appointments in August 2025 signaled a clear repositioning toward immunology focus.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eOrganizational Event\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eAssociated Financial\/Clinical Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClosing of Private Placement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAugust 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to approximately \u003cstrong\u003e$103 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND Clearance for SL-325\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAugust 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSL-325 is a DR3 blocking antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoard Appointments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAugust 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected cash runway into \u003cstrong\u003e2029\u003c\/strong\u003e (pro forma, assuming full warrant exercise)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the value is realized through the guidance these specific members provide over their tenure.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe financing proceeds, assuming full exercise of common stock warrants, are expected to fund operations into \u003cstrong\u003e2029\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Board additions, alongside the financing and IND clearance, marked a repositioning as an \u003cstrong\u003eimmunology and inflammation focused organization\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDirector Status\u003c\/th\u003e\n\u003cth\u003eName\u003c\/th\u003e\n\u003cth\u003eAffiliation\/Role Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAppointed\u003c\/td\u003e\n\u003ctd\u003eDaniel Baker, M.D.\u003c\/td\u003e\n\u003ctd\u003eIndustry expert; previously VP, Immunology R\u0026amp;D at J\u0026amp;J (\u003cstrong\u003e2000-2019\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAppointed\u003c\/td\u003e\n\u003ctd\u003eMona Ashiya, Ph.D.\u003c\/td\u003e\n\u003ctd\u003eMember at OrbiMed Advisors LLC (since \u003cstrong\u003e2010\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStepped Down\u003c\/td\u003e\n\u003ctd\u003eTyler Brous\u003c\/td\u003e\n\u003ctd\u003eOutgoing Director\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStepped Down\u003c\/td\u003e\n\u003ctd\u003eCarrie Brownstein, M.D.\u003c\/td\u003e\n\u003ctd\u003eOutgoing Director\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStepped Down\u003c\/td\u003e\n\u003ctd\u003eMichael Lee\u003c\/td\u003e\n\u003ctd\u003eOutgoing Director\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStepped Down\u003c\/td\u003e\n\u003ctd\u003eKate Sasser, Ph.D.\u003c\/td\u003e\n\u003ctd\u003eOutgoing Director\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eShattuck Labs, Inc. (STTK) - VRIO Analysis: Eighth Core Capabilities \/ Resources: Data-Driven Rationale for Superior Efficacy\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Preclinical data showing high affinity binding and superior activity over existing TL1A antibodies provides a strong basis for future pricing and market positioning.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many drugs enter trials, but clear preclinical differentiation is a strong selling point.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can generate similar data, but Shattuck Labs has the first-mover advantage with this specific data set.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this data was used to secure the IND clearance and the recent \u003cstrong\u003e$103 million\u003c\/strong\u003e financing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this advantage erodes as competing clinical data emerges.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePreclinical Efficacy Metrics for SL-325:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Finding\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBinding Affinity to DR3\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.3 pM\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePicomolar binding affinity to DR3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReceptor Occupancy (NHP)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eFull Occupancy\u003c\/strong\u003e, durable for \u0026gt;\u003cstrong\u003e28 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eObserved at $\\geq \\mathbf{1 \\text{ mg\/kg}}$ dose in non-human primate (NHP) studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTL1A Neutralization Potency (vs. Anti-TL1A)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e43-fold more potent\u003c\/strong\u003e than the next most potent anti-TL1A antibody\u003c\/td\u003e\n\u003ctd\u003eIn an assay measuring apoptosis induced by exogenous TL1A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTL1A Binding Inhibition ($\\text{IC}_{50}$ to DR3)\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e0.06 and 0.30 nM\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eInhibition of human TL1A binding to DR3 in a competition ELISA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgonism Profile\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eLack of DR3 agonism\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eObserved in preclinical results presented at ECCO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial and Clinical Milestones Supporting Organization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIND application for SL-325 submitted in July 2025; clearance occurred in August 2025.\u003c\/li\u003e\n\u003cli\u003ePhase 1 clinical trial dosing of first participant expected in the third quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eOversubscribed private placement closed for up to approximately \u003cstrong\u003e$103 million\u003c\/strong\u003e in gross proceeds.\u003c\/li\u003e\n\u003cli\u003ePro forma cash and cash equivalents, assuming full exercise of common stock warrants, expected to fund planned operations into \u003cstrong\u003e2029\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and Cash Equivalents and Investments as of September 30, 2025, were \u003cstrong\u003e$86.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss for Q2 2025 was \u003cstrong\u003e$12.5 million\u003c\/strong\u003e ($0.24 per share), compared to a $21.6 million loss in Q2 2024.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) Expenses for Q2 2025 were \u003cstrong\u003e$8.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eShattuck Labs, Inc. (STTK) - VRIO Analysis: Ninth Core Capabilities \/ Resources: Focused Operational Expense Management\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Efficient use of capital, leading to a longer cash runway and lower burn rate relative to prior periods.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many peers struggle with uncontrolled spending as they advance assets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a function of specific management decisions made in 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; operational discipline is demonstrated through significant reductions in operating expenses and a narrowing net loss.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expenses decreased from \u003cstrong\u003e$19.2 million\u003c\/strong\u003e in Q2 2024 to \u003cstrong\u003e$8.7 million\u003c\/strong\u003e in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative (G\u0026amp;A) expenses decreased from \u003cstrong\u003e$5.3 million\u003c\/strong\u003e in Q2 2024 to \u003cstrong\u003e$4.4 million\u003c\/strong\u003e in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eNet loss narrowed to \u003cstrong\u003e$10.1 million\u003c\/strong\u003e for the quarter ended September 30, 2025, compared to a net loss of \u003cstrong\u003e$16.6 million\u003c\/strong\u003e for the quarter ended September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents and short-term investments were approximately \u003cstrong\u003e$86.1 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eCurrent cash, assuming the full exercise of outstanding common stock warrants from the August 2025 private placement of up to \u003cstrong\u003e$103 million\u003c\/strong\u003e, is expected to fund operations into \u003cstrong\u003e2029\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development Expense\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development Expense\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; efficiency can fluctuate based on clinical trial needs, but the current discipline is a near-term strength.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e draft 2026 budget scenario analysis by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516258738325,"sku":"sttk-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sttk-vrio-analysis.png?v=1740214588","url":"https:\/\/dcf-model.com\/products\/sttk-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}